Background: The molecular recognition theory predicts that binding domains of peptide hormones and their corresponding receptor binding domains evolved from complementary strands of genomic DNA, and that a process of selective evolutionary mutational events within these primordial domains gave rise to the high affinity and high specificity of peptide hormone-receptor interactions observed today in different peptide hormone-receptor systems. Moreover, this theory has been broadened as a general hypothesis that could explain the evolution of intermolecular protein-protein and intramolecular peptide interactions. Materials and Methods: Applying a molecular cloning strategy based on the molecular recognition theory, we screened a rat kidney cDNA library with a vasopressin (AVP) antisense oligonucleotide probe, expecting to isolate potential AVP receptors.
Introduction
Arginine-vasopressin (AVP) is a nonapeptide hormone with a diverse spectrum of biological effects in almost every organ system. Briefly, it is involved in salt and water balance in the kidney (1); increased glycogenolysis and gluconeogenesis in the liver (1); chronotrophy and inotropy of the heart (1); increased fluid secretion in the ciliary body and blood-brain barrier (1) ; modulation of specific neuronal activation and animal behavior, particularly memory retention, in the central nervous system (1); paracrine regulation of gonadal functions (1); and regulation of blood pressure (2) (3) (4) .
With such markedly diverse biological responses, it is not surprising that receptor isoform diversity constitutes a mechanism for said functional diversity. AVP receptors have been classified as V1-type AVP receptors, which are functionally coupled to Ca 2ϩ mobilization through enhanced inositol lipid breakdown (5, 6) , and V2-type vasopressin receptors, which are functionally coupled to adenylate cyclase (1, 5) and have a ligand specificity identical to that of vasopressin receptors involved in the antidiuretic response to vasopressin. Several groups have recently cloned V1-type (7, 8) and V2-type (9,10) vasopressin receptors using standard expression cloning-and hybridization/polymerase chain reaction (PCR)-based strategies. We recently identified two novel receptors, the AngII/AVP receptor (11) and the ET-1/AngII receptor (12) , utilizing the molecular recognition theory (MRT) as our strategic molecular framework.
The MRT postulates that complementary nucleotide sequences can specify peptides that could interact through complementary structures as a result of their inverted pattern of amino acid hydropathy (13) . This prediction is based on the fundamental observation that the hydropatic character of an amino acid appears to be determined by the second base of a particular codon (13) . Thus, a second base U will generally specify hydrophobic amino acids, in contrast to a second base A, which will specify hydrophilic amino acids (13) . The MRT further implies that peptide hormones and corresponding receptors evolved from complementary strands of genomic DNAs. We present herein the isolation, characterization, and functional expression of a cDNA encoding a novel V1-type AVP receptor. It is the second AVP receptor isoform cloned using a cDNA screening strategy based on MRT, and thus provides insight into the evolutionary origin of the AVP ligand-receptor system.
Materials and Methods

cDNA Screening and Nucleotide Sequencing
An oligonucleotide was synthesized (Research Genetics, Huntsville, AL, USA) based on the cRNA sequence of the rat AVP mRNA (14) corresponding to the AVP antipeptide as follows: TCC-TCT-TGG-GCA-GTT-CTG-GAA-GTA-GC. A gt11 rat kidney cDNA library (10 6 PFU) was hybridized with 10 6 cpm ml Ϫ1 32 P-end labeled oligonucleotide probe at 37ЊC overnight in the following buffer: 6X SSPE (1 M NaCl, 60 mM NaH 2 PO 4 [pH 7.4], 6 mM EDTA [pH 7.4]), 100 g ml Ϫ1 of denatured calf thymus DNA, 0.1% sodium pyrophosphate, 1% SDS (sodium dodecyl sulfate), and 100 g ml Ϫ1 of polyadenylic acid. Washes were done in 2X SSPE (sodium chloride, sodium phosphate EDTA) or (0.36 M NaCl, 20mM Na 2 HPO 4 , 2mM EDTA [pH 7.4]) 0.1% pyrophosphate, and 0.1% SDS at 40ЊC for three 15-min intervals. Nine clones were isolated and plaque purified. Among these clones, the V6 cDNA (ϳ1.7 kb) was subcloned into pSP73 plasmid vector and subsequently sequenced on both strands as described (11, 12) . The cDNA nucleotide sequence data for the novel V1 type AVP receptor presented in this paper will appear in the GenBank database under the accession number AF336872.
Northern Blot Analysis
Northern blot analysis was performed essentially as described (15) . Total RNA was isolated from different tissues from Sprague-Dawley rats. Total RNA (5 g per lane) was size separated on a 1% agarose formaldehyde gel, transferred to nitrocellulose, and hybridized to the 32 P-labelled 1.7-kb V6 cDNA. The blot was washed and exposed for 24 hr at Ϫ80ЊC with intensifying screens.
Transfection and Isolation of Transfected Cos1 Cells
Cos-1 cells (green monkey kidney cells, ATCC) were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and antibiotics (Gibco, Rockville, MD, USA). For expression studies, the 1.7-kb V6 cDNA previously subcloned in the EcoRI site of pSP73 transcription vector (Promega, Madison, WI, USA) was excised using SmaI and EcoRV restriction enzymes. The SmaI/EcoRV 1.7-kb V6 cDNA insert was then subcloned in both orientations into the blunt-ended NheI site of the pMAMneo expression vector (Clontech, Palo Alto, CA, USA). The two V6-pMAMneo recombinants, (ϩ) and (Ϫ), were then transfected into Cos-1 cells via the calcium phosphate precipitate method (16) . A mixed population of stable neomycin-resistant transfectants, Cos1pMAM-V6 (ϩ) and (Ϫ) cells, were selected with 500 g ml Ϫ1 G418 antibiotic (effective concentration ϭ 250 g ml Ϫ1 as per manufacturer's specifications [Gibco] ) and maintained in G418 for expression studies. pMAMneo transfected Cos-1 cells were developed in parallel as controls.
Binding Assays
Binding experiments were done as described (17) with the following specifications. Each assay point consisted of 10 6 cells cultured in P-35 dishes; binding assays were done in 1 ml of binding buffer (17) 45 Ca 2ϩ media and rapid sequential washings and aspirations with three 1 ml aliquots of physiologic buffer (PB; composition in millimolar concentrations: NaCl 140; KCl 5.4; CaCl 2 1.8; MgCl 2 1.6; D-glucose 5.5; Hepes 5, pH 7.4). One milliliter of assay solution containing appropriate ligands dissolved in PB was promptly added and efflux was allowed to proceed for the specific time intervals. Efflux was terminated by rapid washing and aspiration with three 1-ml aliquots of MgCl 2 -free PB containing 5 mM LaCl 3 . Residual 45 Ca 2ϩ content was expressed relative to total isotope present in cultures that received the wash protocol without any intervening efflux interval (time zero averaged 9000 Ϯ 857 cpm per P-35 dish). All assays were done at 37ЊC.
Inositol Phosphate Accumulation
Inositol phosphate measurements were done as follows. Cells (confluent P-35 dishes) were incubated in a buffer containing 130 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 10 mM glucose, and 20 mM Hepes, pH 7.4, with or without hormone. After exposure to hormone or buffer (1 ml per dish, 37ЊC for 10-30 sec), the reaction was terminated by rapid aspiration of incubation buffer and subsequent addition of 1 ml of ice-cold 10% trichloroacetic acid. Cells were then scraped with a rubber policeman and the entire content of the dish was transferred to a test tube. After centrifugation (10,000 g ϫ 10 min), (20), we hypothesized that the V6 cDNA might encode a V1-type AVP receptor.
Structural Analysis of the V6 cDNA
The nucleotide sequence (Fig. 2) of the 1.7-kb V6 cDNA revealed an open reading frame (ORF) containing a typical initiating methionine with 9 of 13 identical nucleotides with the Kozak consensus sequence (21) . The deduced resultant polypeptide is 135 amino acids long.
Comparison with the nucleotide sequence of the AVP antipeptide-based oligonucleotide probe revealed only one region with the highest degree of nucleotide identity, 19 nucleotides over a stretch of 22 nucleotides (86%) (Fig. 2A) . This marks the putative AVP binding site based on the MRT. We note the antisense peptide from frame 2 (Fig. 2C) as the putative evolutionary AVP precursor binding domain. Analysis of the hydropathy profile of the V6 cDNA encoded polypeptide based on the Kyte-Doolittle scale using an amino acid window of 17 for analysis (22, 23 ) reveals a single putative transmembrane domain ( Fig. 2A) . The identification of a putative AVP binding domain and a single putative transmembrane region places the N-terminus extracellularly, and the C-terminus intracellularly. The C-terminal intracellular domain has one potential protein kinase C (PKC)-phosphorylation site whose function remains to be determined.
Functional and Pharmacologic Characterization of the V6 cDNA Encoded AVP Receptor
The V6 cDNA clone was subcloned into the pMAMneo expression vector in two orientations and transthe protein precipitate was discarded and the supernatant was extracted three times with equal volumes of diethyl ether. 
Immunocytochemistry
A polyclonal rabbit antipeptide antibody (custommade by Multiple Peptide Systems, San Diego, CA, USA) was raised against the synthetic peptide L 11 WLPEDGQVR 20 spanning a portion of the predicted extracellular domain of the V6-encoded vasopressin receptor (Fig. 2) . Control Cos1pMAMneo and test Cos1pMAM-V6 cells were reacted with this antibody (1:500) and immunostained as described previously (11, 12) . Cells were blocked in phosphatebuffered saline (PBS) plus 1% bovine serum albumin (BSA) for 30 min at 4ЊC. Cells were reacted with primary antibody in PBS plus 1% BSA for 14 hr at 4ЊC. After two washes with PBS at 4ЊC, cells were fixed with Bouin's solution (Sigma, St. Louis, MO, USA) for 15 sec at room temperature. After extensive washing with PBS, cells were sequentially reacted with biotinylated goat anti-rabbit IgG (BioRad, Hercules, CA, USA), followed by streptavidin 10 nM colloidal gold labeled and finally subjected to silver enhancement. No immunostaining was observed on Cos1pMAM-V6 cells when the antipeptide antibody was coincubated with the antigenic peptide (1 mM) or replaced by preimmune serum at a 1:500 dilution.
Results
Isolation and Tissue Distribution of V6 cDNA
The molecular recognition theory states that peptide ligands and their receptor binding sites could have evolved from complementary nucleotide sequences (19) . We took this notion one step further and applied it to the screening of putative AVP receptor cDNA clones. Using the rat AVP antipeptide-based oligonucleotide as the hybridization probe, we isolated nine cDNA clones from a rat kidney cDNA library. Three of the clones were identified and encoded the dual AngII/AVP receptor that we recently characterized (11) . The next largest cDNA clone, V6 (1.7 kb), was then analyzed. This cDNA did not crosshybridize with the previously characterized cDNA encoding the AngII/AVP receptor (data not shown). Northern blot analysis at stringent hybridization conditions revealed two mRNAs: 3.0 kb and 3.5 kb (Fig. 1) . The mRNAs were detected in all tissues tested with the following relative abundance: rat aortic smooth muscle cells (A-10 cells, ATCC) Ͼ adrenal gland (Adr.Gl.) Ͼ pulmonary vas- fected into Cos-1 cells followed by G418 antibiotic selection. pMAMneo G418-resistant cells were developed in parallel and served as controls. Based on the hypothesis that the V6 cDNA might encode a V1-type AVP receptor, we investigated AVP-induced V6 cDNA-receptor coupling to Ca 2ϩ mobilization. As predicted, only one orientation, pMAM-V6 (ϩ), expressed a functional AVP-responsive cell membrane receptor (as measured by 45 (Fig. 3C) . Analyzing the percent activity of 45 Ca 2ϩ efflux induced at varying concentrations of AVP (10 Ϫ13 to 10 Ϫ7 M), a dose-response curve with an EC 50 of 50 pM was exhibited by Cos1pMAM-V6 cells.
To study the coupling of the V6 encoded receptor to early cellular biochemical events responsible for the calcium flux, we investigated the AVPinduced phospholipase C-mediated phosphoinositide hydrolysis in Cos1pMAM-V6 cells. As shown in Figure 3D , 0.1 M of AVP induced IP3 formation in Cos1pMAM-V6 cells peaking at 10 sec. The time course is consistent with the AVP-induced phosphoinositide hydrolysis being an early event responsible for the AVP-induced Ca 2ϩ mobilization. Moreover, when we analyzed the IP3 formation induced at varying concentrations of AVP (10
Ϫ12
-10 Ϫ7 M), a dose response curve with an EC 50 of 50 pM was exhibited by Cos1pMAM-V6 cells (Fig. 3E) . This value is consistent with the Ca 2ϩ efflux measurements (Fig. 3C) and further confirms the specificity of the AVP response.
The functional coupling of an AVP responsive receptor to a Ca 2ϩ mobilizing transduction system via phospholipase C-mediated phosphoinositide hydrolysis suggests a V1-type AVP receptor (5, 6) . To further investigate this, we analyzed the agonist/ antagonist pharmacologic response profile of V6-encoded receptors on intact Cos1pMAM-V6 cells. As seen in Figure 3F and Table 1 , the pharmacologic profile of the V6-encoded receptor analyzed by displacement of 
Topography of the V6 cDNA Encoded Vasopressin Receptor
To ascertain the predicted topography of the V6 cDNA encoded AVP receptor, we performed immunocytochemical studies on intact (nonpermeabilized) Cos1pMAM-V6 transfectants utilizing a polyclonal antipeptide antibody raised against amino acids 11-20 of the predicted extracellular domain (Fig. 2) . As shown in Figure 4 , prominent staining was observed in pMAM-V6 transfectants Fig. 2 ). Primary antibody was reacted with intact cells followed by immunostaining as described in Materials and Methods.
( Fig. 4B ) in contrast to no staining in control Cos1pMAMneo transfectants (Fig. 4A) , thus corroborating the predicted topography and cell membrane localization of the V6 vasopressin type-1 receptor.
Discussion
Several characteristics of the V6 cDNA encoded AVP receptor strongly suggest that it is of the V1-type. The V6 mRNA tissue distribution is consistent with the tissue distribution of V1 receptors detected pharmacologically (1, 5, 6) . Its predominance in vascular tissue and smooth muscle cells is also consistent with the tissue distribution of vasopressor V1-type AVP receptors (1, 5, 6) . Moreover, the specificity for AVP as ligand (K d ϭ 6 nM), the functional coupling to a transduction system that mobilizes Ca 2ϩ (EC 50 ϭ 50 pM), and the greater affinity for a V1 antagonist (K i ϭ 250 nM) over a dual V1/V2 antagonist and a potent V2 agonist, DVDAVP, (K i ϭ 600 nM for both) are strong evidence supporting the notion that the V6 cDNA encodes an AVP receptor of the V1 type. In contrast, the previously characterized AngII/AVP V2-type receptor exhibits a K i of 109 nM for DVDAVP, and a K i above 13,000 nM for the same V1 antagonist (27) (11) . This would indicate that different amino acid sequences could fulfill the structural requirements for AVP binding as was previously observed for AngII binding by the AngII/AVP receptor (11) and ET-1/AngII receptor (12) AngII binding domains. We note that the precise amino acid(s) that contact AVP within this predicted AVP binding domain remain to be determined through specific sitedirected mutagenesis and/or crystallographic studies.
Analysis of nucleotide and deduced amino acid sequence homology with other cloned vasopressin receptors (7) (8) (9) (10) and with other representative members of the seven transmembrane domains G protein-coupled receptor superfamily (28, 29) revealed no sequence identity. A similar topography (a single transmembrane domain) was also observed in the recently reported ET-1/AngII receptor (12) that was identified on the basis of the MRT as well. These observations are consistent with the MRT as the basis of the evolutionary origin of AVP, AngII, and ET-1 receptors. It is conceivable that in the evolution of these receptors, exon shuffling of the antipeptide oligonucleotides occurred into different membrane-spanning proteins, thus accounting for the quite different polypeptide sequences but conserved antipeptide-derived putative binding domain regions observed in today's receptors. Nevertheless, the isolation of two types of AVP receptors in the single cDNA screening done with the AVP antipeptidebased oligonucleotide probe, the AngII/AVP receptor (11) and the V6 cDNA-encoded vasopressin V1-type receptor reported here, supports the molecular recognition theory as the basis of the evolution of the AVP ligand-receptor system. Numerous studies have reported experimental evidence in support of this theory (see references 11,30 and citations therein). However, the MRT remains controversial; some biochemical and theoretical analyses testing the potential validity of the MRT have reported negative results (31) (32) (33) (34) (35) (36) (37) . Nevertheless, our studies underscore the importance of investigating other peptide-hormone receptor systems for a full understanding of their evolution and function, as well as to gain further insights into the general applicability of the molecular recognition theory to the evolution of the presently known biological systems.
